ATE213413T1 - Verwendung von 3-(4-hexyloxy-1,2,5-thiadiazol-3- yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) zur behandlung von bipolaren störungen - Google Patents
Verwendung von 3-(4-hexyloxy-1,2,5-thiadiazol-3- yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) zur behandlung von bipolaren störungenInfo
- Publication number
- ATE213413T1 ATE213413T1 AT97305585T AT97305585T ATE213413T1 AT E213413 T1 ATE213413 T1 AT E213413T1 AT 97305585 T AT97305585 T AT 97305585T AT 97305585 T AT97305585 T AT 97305585T AT E213413 T1 ATE213413 T1 AT E213413T1
- Authority
- AT
- Austria
- Prior art keywords
- xanomeline
- methylpyridine
- hexyloxy
- thiadiazole
- tetrahydro
- Prior art date
Links
- 208000020925 Bipolar disease Diseases 0.000 title abstract 2
- JOLJIIDDOBNFHW-UHFFFAOYSA-N xanomeline Chemical compound CCCCCCOC1=NSN=C1C1=CCCN(C)C1 JOLJIIDDOBNFHW-UHFFFAOYSA-N 0.000 title 2
- 229950006755 xanomeline Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Nonmetallic Welding Materials (AREA)
- Steroid Compounds (AREA)
- Processing Of Solid Wastes (AREA)
- Press Drives And Press Lines (AREA)
- Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2290096P | 1996-08-01 | 1996-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE213413T1 true ATE213413T1 (de) | 2002-03-15 |
Family
ID=21812011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97305585T ATE213413T1 (de) | 1996-08-01 | 1997-07-25 | Verwendung von 3-(4-hexyloxy-1,2,5-thiadiazol-3- yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) zur behandlung von bipolaren störungen |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0821955B1 (de) |
| JP (1) | JP2000515547A (de) |
| KR (1) | KR20000029647A (de) |
| CN (1) | CN1226165A (de) |
| AT (1) | ATE213413T1 (de) |
| AU (1) | AU716972B2 (de) |
| BR (1) | BR9710901A (de) |
| CA (1) | CA2261802C (de) |
| CZ (1) | CZ27299A3 (de) |
| DE (1) | DE69710526T2 (de) |
| DK (1) | DK0821955T3 (de) |
| EA (1) | EA199900174A1 (de) |
| ES (1) | ES2171838T3 (de) |
| HU (1) | HUP9904578A2 (de) |
| IL (1) | IL128280A0 (de) |
| NO (1) | NO990436D0 (de) |
| PL (1) | PL331407A1 (de) |
| PT (1) | PT821955E (de) |
| WO (1) | WO1998005324A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3061821B1 (de) | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Zusammensetzungen zur behandlung von durch muscarinrezeptoraktivierung gelinderten leiden |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| IL281809B (en) | 2018-09-28 | 2022-09-01 | Karuna Therapeutics Inc | Compositions and methods for the treatment of diseases improved by the activation of muscarinic receptors |
| CN111430027B (zh) * | 2020-03-18 | 2023-04-28 | 浙江大学 | 基于肠道微生物的双相情感障碍生物标志物及其筛选应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| US5376668A (en) * | 1990-08-21 | 1994-12-27 | Novo Nordisk A/S | Heterocyclic compounds |
| DK0734259T3 (da) * | 1993-08-19 | 2002-09-30 | Novo Nordisk As | Antipsykotisk fremgangsmåde |
| US5821370A (en) * | 1994-10-24 | 1998-10-13 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| WO1996013167A1 (en) * | 1994-10-31 | 1996-05-09 | Eli Lilly And Company | Method for treating anxiety |
| US5488056A (en) * | 1994-10-31 | 1996-01-30 | Eli Lilly And Company | Method for treating anxiety |
-
1997
- 1997-07-25 EP EP97305585A patent/EP0821955B1/de not_active Expired - Lifetime
- 1997-07-25 PT PT97305585T patent/PT821955E/pt unknown
- 1997-07-25 ES ES97305585T patent/ES2171838T3/es not_active Expired - Lifetime
- 1997-07-25 DE DE69710526T patent/DE69710526T2/de not_active Expired - Lifetime
- 1997-07-25 AT AT97305585T patent/ATE213413T1/de active
- 1997-07-25 DK DK97305585T patent/DK0821955T3/da active
- 1997-07-28 BR BR9710901A patent/BR9710901A/pt not_active Application Discontinuation
- 1997-07-28 IL IL12828097A patent/IL128280A0/xx unknown
- 1997-07-28 PL PL97331407A patent/PL331407A1/xx unknown
- 1997-07-28 KR KR1019997000720A patent/KR20000029647A/ko not_active Withdrawn
- 1997-07-28 EA EA199900174A patent/EA199900174A1/ru unknown
- 1997-07-28 CN CN97196820A patent/CN1226165A/zh active Pending
- 1997-07-28 AU AU40468/97A patent/AU716972B2/en not_active Ceased
- 1997-07-28 JP JP10508002A patent/JP2000515547A/ja not_active Ceased
- 1997-07-28 WO PCT/US1997/013185 patent/WO1998005324A1/en not_active Ceased
- 1997-07-28 CA CA002261802A patent/CA2261802C/en not_active Expired - Lifetime
- 1997-07-28 CZ CZ99272A patent/CZ27299A3/cs unknown
- 1997-07-28 HU HU9904578A patent/HUP9904578A2/hu unknown
-
1999
- 1999-01-29 NO NO990436A patent/NO990436D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU4046897A (en) | 1998-02-25 |
| CN1226165A (zh) | 1999-08-18 |
| CA2261802C (en) | 2006-11-07 |
| BR9710901A (pt) | 1999-08-17 |
| JP2000515547A (ja) | 2000-11-21 |
| EA199900174A1 (ru) | 1999-08-26 |
| EP0821955A2 (de) | 1998-02-04 |
| EP0821955A3 (de) | 1998-04-22 |
| IL128280A0 (en) | 1999-11-30 |
| AU716972B2 (en) | 2000-03-09 |
| DE69710526T2 (de) | 2002-10-02 |
| PL331407A1 (en) | 1999-07-19 |
| DK0821955T3 (da) | 2002-03-18 |
| CA2261802A1 (en) | 1998-02-12 |
| CZ27299A3 (cs) | 1999-08-11 |
| EP0821955B1 (de) | 2002-02-20 |
| PT821955E (pt) | 2002-07-31 |
| NO990436L (no) | 1999-01-29 |
| KR20000029647A (ko) | 2000-05-25 |
| WO1998005324A1 (en) | 1998-02-12 |
| ES2171838T3 (es) | 2002-09-16 |
| HUP9904578A2 (hu) | 2000-06-28 |
| DE69710526D1 (de) | 2002-03-28 |
| NO990436D0 (no) | 1999-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69729946D1 (de) | Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia | |
| DE69634733D1 (de) | Benzamidoxime prodrugs und verwendung zur behandlung von pneumonie | |
| DE60012751D1 (de) | Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz | |
| FI935529A0 (fi) | Aminometylensubstituerade icke-aromatiska heterocykliska foereningar | |
| ATE209490T1 (de) | Substanz p antagonisten zur behandlung von erbrechen | |
| ATE218576T1 (de) | Phosphohalohydrine, verfahren zu deren herstellung und verwendungen | |
| EP0758894A4 (de) | Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie | |
| ATE212548T1 (de) | Behandlung und prophylaxe von pankreatitis | |
| ATE156359T1 (de) | Phosphatdiester zur behandlung von proliferativen erkrankungen der epidermis | |
| DE69710526D1 (de) | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen | |
| DE69816244D1 (de) | Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms | |
| ATE222491T1 (de) | Melatonin-derivate zur verwendung in der behandlung von schlafstörungen | |
| DE69432626D1 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen | |
| ATE209914T1 (de) | Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen | |
| DE69713571D1 (de) | Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1(2-(4-fluorophenyl)ethyl-4-piperidinmethanol zur behandlung von depressionen und bipolaren erkrankungen | |
| NO20003481L (no) | FremgangsmÕte for behandling av COPD | |
| ATE267018T1 (de) | Verwendung von peptidverbindungen zur behandlung von sle | |
| EP0821957A3 (de) | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch | |
| DE69614936D1 (de) | d4T polymorphe Form I Verfahren | |
| ATE470671T1 (de) | Verbindungen mit wachstumshormon-freisetzender eigenschaft | |
| DE60007078D1 (de) | Verwendung von antikonvulsiven derivaten zur behandlung von bulimia nervosa | |
| DE60013515D1 (de) | 4-Arylpiperidinderivate zur Behandlung von Pruritus | |
| DE69823650D1 (de) | Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs | |
| ATE283269T1 (de) | 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems | |
| DE69221649D1 (de) | Lacidipin zur Behandlung der Arteriosklerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |